UK Regulatory Landscape post Brexit
Following the UK’s departure from the EU, the MHRA is the UK’s standalone medicines and medical devices regulator. To launch and / or maintain successful drug development programs in the UK, sponsors need to be aware of the new regulatory requirements and procedures.
From 1 January 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) introduced changes to licensing procedures, including adding procedures to prioritise access to new medicines
In this webinar, Dr Thomas Lönngren and Patrick Mumo provide early initial insights into the changing UK regulatory landscape post brexit as the industry continues to adapt to the post-transition period.
Fill out the form on the right to download this article.
Your drug development needs are unique
Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.
Let's Bring Medicines to the World